- Trials with a EudraCT protocol (239)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
239 result(s) found for: Viral entry.
Displaying page 1 of 12.
EudraCT Number: 2015-004042-26 | Sponsor Protocol Number: PrEP-CS-002 | Start Date*: 2015-11-17 | |||||||||||
Sponsor Name:hVIVO Services Limited | |||||||||||||
Full Title: A Phase II, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Asthmatic Subjects Subsequently Challenged with Human Rhinoviru... | |||||||||||||
Medical condition: Human Rhinovirus (HRV-16) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003887-21 | Sponsor Protocol Number: HVO-CS-005 | Start Date*: 2020-11-03 |
Sponsor Name:hVIVO Services Limited | ||
Full Title: A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of A Respiratory Syncytial Virus Vaccine (RSVpreF) in A Virus Challenge Model in H... | ||
Medical condition: Respiratory Syncytial Virus Infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001044-26 | Sponsor Protocol Number: MB05-P-01-20 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:mAbxience Research S.L. | |||||||||||||
Full Title: A Double-Blind, Randomised, Placebo-Controlled Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated with Respiratory Syncytial Virus (RSV) | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000524-14 | Sponsor Protocol Number: MTF-C-019 | Start Date*: 2006-06-22 |
Sponsor Name:ViraNative AB | ||
Full Title: Comparison of virological response during high and low-dose regimen with natural IFN α in combination with ribavirin in patients with genotype 1 chronic hepatitis C who have experienced an incomple... | ||
Medical condition: Chronic hepatitis C, genotype 1 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001107-20 | Sponsor Protocol Number: MDT-637-CP-201 | Start Date*: 2013-08-02 | |||||||||||
Sponsor Name:MicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd. | |||||||||||||
Full Title: A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b) | |||||||||||||
Medical condition: RSV Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001769-27 | Sponsor Protocol Number: CHI0465 | Start Date*: 2008-09-29 |
Sponsor Name:Southampton University Hospital Trust | ||
Full Title: Microbiological assessment of prophylactic ciprofloxacin therapy for children with cystic fibrosis during viral respiratory viral infection to prevent Pseudomonas aeruginosa colonisation – a random... | ||
Medical condition: Cystic Fibrosis Specifically the trial will include children aged 2-14 years with a diagnosis of cystic fibrosis and not chronically infected with pseudomonas aeruginosa in their lungs. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003106-24 | Sponsor Protocol Number: 721103 | Start Date*: 2011-10-06 |
Sponsor Name:Baxter Innovations GmbH | ||
Full Title: Effectiveness of PREFLUCEL vaccination against infection with seasonal influenza virus in an adult and elderly population aged 50 years and older | ||
Medical condition: To verify the effectiveness of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2011/2012 and 2012/2013 season respectively, manufactured us... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004296-77 | Sponsor Protocol Number: BTA585-003 | Start Date*: 2016-02-08 |
Sponsor Name:Biota Pharma Europe Limited | ||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral... | ||
Medical condition: Respiratory Syncytial Virus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001536-36 | Sponsor Protocol Number: EARLY-HEP-C | Start Date*: 2016-08-03 | ||||||||||||||||
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||||||||||||||||||
Full Title: Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV co-infected patients | ||||||||||||||||||
Medical condition: Early Chronic Hepatitis C in HIV/HCV co-infected patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002234-53 | Sponsor Protocol Number: eCLEAR-001 | Start Date*: 2016-11-14 | |||||||||||
Sponsor Name:Department of Infectious Diseases, Aarhus University Hospital | |||||||||||||
Full Title: Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a random... | |||||||||||||
Medical condition: HIV persistence during initiation of antiretroviral therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004036-30 | Sponsor Protocol Number: ALS-8176-502 | Start Date*: 2013-11-29 | |||||||||||
Sponsor Name:Alios BioPharma | |||||||||||||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respirator... | |||||||||||||
Medical condition: Respiratory Syncytial Virus (RSV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002134-74 | Sponsor Protocol Number: FLU-v004 | Start Date*: 2016-07-27 | |||||||||||
Sponsor Name:PepTcell Limited (trade name SEEK) | |||||||||||||
Full Title: Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model | |||||||||||||
Medical condition: Influenza virus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002232-85 | Sponsor Protocol Number: 5172-017 | Start Date*: 2013-01-15 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. | |||||||||||||
Full Title: A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in ... | |||||||||||||
Medical condition: Hepatitis C Virus Infection (HCV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) SE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) HU (Completed) ES (Completed) FI (Completed) NL (Completed) LT (Completed) EE (Completed) CZ (Completed) NO (Completed) AT (Completed) PL (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014406-34 | Sponsor Protocol Number: ORVACS-010 | Start Date*: 2010-05-28 | |||||||||||
Sponsor Name:ORVACS | |||||||||||||
Full Title: International, multicenter, randomized, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV patients with long-term viral suppression | |||||||||||||
Medical condition: HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) GB (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001676-21 | Sponsor Protocol Number: V48P7E1 | Start Date*: 2006-08-14 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics GmbH & Co. KG | |||||||||||||
Full Title: A phase IV, open-label, single-center study in adolescents and adults: Evaluation of immunogenicity and safety of the first booster immunization with Chiron’s TBE vaccine for adults in participants... | |||||||||||||
Medical condition: TBE prophylaxis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001878-21 | Sponsor Protocol Number: EDP938-101 | Start Date*: 2018-10-05 | |||||||||||
Sponsor Name:ENANTA Pharmaceuticals, Inc | |||||||||||||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Pharmacokinetics And Antiviral Activity Of Multiple Doses Of Orally Administered EDP-938 Against Respiratory S... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001983-52 | Sponsor Protocol Number: GV28985 | Start Date*: 2013-09-19 | |||||||||||||||||||||
Sponsor Name:Genentech Inc. | |||||||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, phase 2a study in healthy volunteers, to evaluate the efficacy and safety of MHAA4549A in an Influenza challenge model | |||||||||||||||||||||||
Medical condition: Treatment of Influenza | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002695-17 | Sponsor Protocol Number: DEB-025-HCV-203 | Start Date*: 2006-09-21 | |||||||||||
Sponsor Name:DEBIOPHARM S.A. | |||||||||||||
Full Title: A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS 180 g/week i... | |||||||||||||
Medical condition: treatment na ve patients with chronic hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000849-50 | Sponsor Protocol Number: MI-CP114 | Start Date*: 2017-12-12 |
Sponsor Name:MedImmune | ||
Full Title: A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of... | ||
Medical condition: The prevention of Influenza Virus in Immunocompromised children ages 5 through 17 years of age. | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-001282-24 | Sponsor Protocol Number: REVCS002 | Start Date*: 2017-06-21 | |||||||||||
Sponsor Name:ReViral Ltd | |||||||||||||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of RV521 Against Respiratory Syncytial Virus infecti... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
